Skip to content
Homepage
Author:
Unicycive Therapeutics, Inc.
Posted Date:
June 30, 2026
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Unicycive Therapeutics, Inc.
June 30, 2026
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics, Inc.
May 12, 2026
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Unicycive Therapeutics, Inc.
May 5, 2026
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Unicycive Therapeutics, Inc.
May 4, 2026
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
Unicycive Therapeutics, Inc.
February 4, 2026
UPDATE – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics, Inc.
January 29, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics, Inc.
January 29, 2026
